In addition, the combination of TRAIL and OSMI-1 shows promise as a therapeutic strategy for overcoming TRAIL resistance in the treatment of colon cancer (Lee S. J. et al., 2021). Here, TNFSF10 is linked to malignant colon neoplasm.